Voinea Silviu, Herghelegiu Cătălin Gabriel, Sandru Angela, Ioan Raluca Gabriela, Bohilțea Roxana Elena, Bacalbașa Nicolae, Chivu Laura Ioana, Furtunescu Florentina, Stanica Diana Catalina, Neacșu Adrian
Department of Surgery, Oncology Institute 'Prof. Dr. Alexandru Trestioreanu', 'Carol Davila' University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Department of Obstetrics and Gynecology, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Exp Ther Med. 2021 Jan;21(1):93. doi: 10.3892/etm.2020.9525. Epub 2020 Nov 26.
Cervical cancer is one of the most common cancers in women in developing countries, second only to breast cancer, with more than 450.000 new cases every year. Romania has the highest incidence of cervical cancer in Europe; more than four times the incidence found in Western Europe. Radiotherapy with or without chemotherapy is considered in most countries the gold standard for locally advanced cervical cancer. In Romania, if downstaging occurs after radiotherapy, adjuvant surgery is routinely performed. Thus, in the present study, we investigated the rate of residual cancer in patients with locally advanced cervical cancer who underwent surgery after concurrent chemoradiotherapy and to determine the impact of tumor histological subtype on the chemoradiotherapy response. Of a total of 461 patients with locally advanced cervical cancer that underwent chemoradiotherapy and adjuvant surgery, 254 had a partial response defined as the presence of residual tumor at pathology examination. Depending on the histological subtype of the cervical cancer, partial response was obtained in 50.6% of squamous cell carcinoma cases and in 77.6% of adenocarcinoma or adenosquamous carcinoma cases. The present study demonstrated that cervical cancer patients with adenocarcinomas and adenosquamous carcinomas had a significantly poorer treatment response to chemoradiotherapy than those with squamous cell carcinomas. We consider that in such cases where residual tumor is present, adjuvant surgery is mandatory for improving the survival rates.
宫颈癌是发展中国家女性中最常见的癌症之一,仅次于乳腺癌,每年新增病例超过45万例。罗马尼亚是欧洲宫颈癌发病率最高的国家,其发病率是西欧的四倍多。在大多数国家,放疗联合或不联合化疗被视为局部晚期宫颈癌的金标准。在罗马尼亚,如果放疗后肿瘤降期,通常会进行辅助手术。因此,在本研究中,我们调查了同步放化疗后接受手术的局部晚期宫颈癌患者的残留癌发生率,并确定肿瘤组织学亚型对放化疗反应的影响。在总共461例接受放化疗和辅助手术的局部晚期宫颈癌患者中,254例有部分反应,定义为病理检查时存在残留肿瘤。根据宫颈癌的组织学亚型,鳞状细胞癌病例中有50.6%获得部分反应,腺癌或腺鳞癌病例中有77.6%获得部分反应。本研究表明,腺癌和腺鳞癌的宫颈癌患者对放化疗的治疗反应明显比鳞状细胞癌患者差。我们认为,在存在残留肿瘤的这种情况下,辅助手术对于提高生存率是必不可少的。